RxDoctor Payments Data

Stephen Frye, MD

Psychiatry · Las Vegas, NVNPI 1164755328

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,251 and has fallen 70.7% since, to $366 in 2025.

$3,585in general payments, 2019–2025

Across 57 payments — averaging $62.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$571
  • AbbVie$527
  • Neurocrine Biosciences, Inc.$492
  • Johnson & Johnson$473
  • Axsome Therapeutics, Inc.$241
  • E.r. Squibb & Sons, L.L.C.$239
  • plus $1K from 11 others

What the payments were for

  • Food & beverage$3,585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,585 in reported general payments places this provider in the 80th percentile of 243 psychiatry providers in Nevada.

See all psychiatry providers in Nevada

Medicare billing

Part B allowed, 2024
$74,110
Medicare patients
13
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl15$21,893
Bupropion XlBupropion Hcl27$908
Trazodone Hcl74$867
Aripiprazole20$818
Alprazolam22$296
Quetiapine Fumarate25$271
Olanzapine16$239
Doxepin Hcl12$216
Mirtazapine34$203
Prazosin Hcl11$177
Fluoxetine Hcl50$177
Duloxetine Hcl12$141
Clonazepam25$116
Zolpidem Tartrate12$68
Lorazepam15$63

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$527$21,89315 claims
Lilly USA, LLCOlanzapine$18$23916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 243 psychiatry providers in Nevada.

Other psychiatry in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →